Education
About Us
Working with TipRanks
Follow Us
Oncimmune Holdings PLC (GB:ONC)
LSE:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.01p - 31.00p
Previous CloseN/A
Volume18.00
Average Volume (3M)116.37K
Market Cap
£1.27M
Enterprise Value17.29M
Total Cash (Recent Filing)£7.51M
Total Debt (Recent Filing)£8.59M
Price to Earnings (P/E)1.3
Beta0.40
Next Earnings
May 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding111,773,220
10 Day Avg. Volume0
30 Day Avg. Volume116,369
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.80
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Oncimmune Holdings News
PremiumCompany Announcements
Oncimmune Holdings Faces Administration and Adviser Resignations
PremiumCompany Announcements
Oncimmune Holdings Announces Change in Major Shareholder Voting Rights
PremiumCompany Announcements
Oncimmune Holdings to Enter Administration and Suspend Trading
PremiumCompany Announcements
Oncimmune Holdings Secures Strong Shareholder Support at General Meeting
PremiumCompany Announcements
Oncimmune Holdings Successfully Passes AGM ResolutionsPremiumCompany Announcements
Oncimmune Seeks Strategic Partnerships Amidst Financial ChallengesPremiumCompany Announcements
Oncimmune Holdings PLC Announce Changes in Shareholder Voting Rights
PremiumCompany Announcements
Oncimmune Announces General Meeting to Approve Financial Report---
Options Prices
Currently, No data available
---
Ownership Overview
1.56% Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
98.44% Public Companies and
Individual Investors
ONC FAQ
What was Oncimmune Holdings PLC’s price range in the past 12 months?
Oncimmune Holdings PLC lowest share price was 1.01p and its highest was 31.00p in the past 12 months.
What is Oncimmune Holdings PLC’s market cap?
Oncimmune Holdings PLC’s market cap is £1.27M.
When is Oncimmune Holdings PLC’s upcoming earnings report date?
Oncimmune Holdings PLC’s upcoming earnings report date is May 28, 2025 which is in 30 days.
How were Oncimmune Holdings PLC’s earnings last quarter?
Oncimmune Holdings PLC released its earnings results on Feb 10, 2025. The company reported -0.034p earnings per share for the quarter, missing the consensus estimate of N/A by -0.034p.
Is Oncimmune Holdings PLC overvalued?
According to Wall Street analysts Oncimmune Holdings PLC’s price is currently Overvalued.
Does Oncimmune Holdings PLC pay dividends?
Oncimmune Holdings PLC does not currently pay dividends.
What is Oncimmune Holdings PLC’s EPS estimate?
Oncimmune Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncimmune Holdings PLC have?
Oncimmune Holdings PLC has 111,773,220 shares outstanding.
What happened to Oncimmune Holdings PLC’s price movement after its last earnings report?
Oncimmune Holdings PLC reported an EPS of -0.034p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Oncimmune Holdings PLC?
Currently, no hedge funds are holding shares in GB:ONC
---
Company Description
Oncimmune Holdings PLC
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
---
Technical Analysis
---